X0609 4 2026-09-10 0001841387 Candel Therapeutics, Inc. CADL 0001873905 Tak Paul Peter false C/O CANDEL THERAPEUTICS, INC. 117 KENDRICK ST., SUITE 450 NEEDHAM MA 02494 true true false false Chief Executive Officer true Common Stock 2026-09-10 4 M false 125000 1.55 A 393566 D Common Stock 2026-09-10 4 S false 220866 11.4997 D 172700 D Common Stock 2026-09-11 4 S false 59379 10.4564 D 113321 D Stock Option (Right to Buy) 1.55 2026-09-10 4 M false 125000 0 D 2030-10-10 Common Stock 125000 1638968 D This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 herein. 25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ Charles Schoch, as Attorney-In-Fact for Paul Peter Tak 2026-09-11